Sector: Health Care
Director information for OMEROS CORP (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Arnold C. Hanish | Director; Chair | 78 | ["Experience in public company finance and accounting","Reporting to the U.S. Securities and Exchange Commission (the SEC)","Management and corporate governance","Knowledge of the pharmaceutical and biotechnology industry","Experience as the chair of the audit committee","Certified Public Accountant","B.A. in accounting from the University of Cincinnati"] | ["Audit"] | 2026 |
| Diana T. Perkinson, M.D. | Director | 72 | ["Dual board certifications in nephrology and internal medicine","Practiced as a physician at MD2 International LLC from 2009 to 2025","Practiced nephrology and internal medicine at Minor & James Medical from 1987 to 2009","Clinical assistant professor in the division of nephrology at the University of Washington from 1987 to 2009","Medical director, transplantation, at Swedish Hospital from 1996 to 2007","Major in the United States Air Force","Director of the dialysis unit at Wilford Hall Medical Center at Lackland Air Force Base from 1984 to 1987","M.D. from the University of Alabama","B.S. from Birmingham Southern College","Completed fellowship in nephrology at the University of Washington"] | ["Nominating and Governance","Scientific","Scientific Committee"] | 2026 |
| Gregory A. Demopulos, M.D. | Chairman of the Board, President, Chief Executive Officer; CEO; Chairman of the Board | 67 | ["Founded the company","Served as president and chief executive officer since June 1994","Experience as chief financial officer and treasurer (interim capacity)","Experience as chief medical officer","Completed residency in orthopedic surgery at Stanford University","Fellowship training in hand and microvascular surgery at Duke University","Recipient of the Prix Galien Canada Research Award in 2019","Serves on the board of trustees of the Smead Funds Trust","M.D. from Stanford University School of Medicine","B.S. from Stanford University","Medical and scientific expertise","Experience with clinical development and design","Detailed knowledge of operations and development programs"] | [] | 2026 |
| Leroy E. Hood, M.D., Ph.D. | Director | 87 | ["Chief strategy officer and professor at the Institute for Systems Biology","Co-founded the Institute for Systems Biology","Founding chief executive officer of Phenome Health","Senior vice president and chief science officer of Providence St. Joseph Health","Founder and chairman of the Department of Molecular Biotechnology at the University of Washington School of Medicine","Co-founded Amgen, Inc., Applied Biosystems, Inc., Darwin Molecular Technologies, Inc., Rosetta Inpharmatics, Inc. and SyStemix, Inc.","Member of the National Academy of Science, the National Academy of Engineering and the National Academy of Medicine","Recipient of numerous national and international awards, including the National Medal of Science, the Lasker Award and the Kyoto Prize","Ph.D. and B.S. from the California Institute of Technology","M.D. from The Johns Hopkins School of Medicine"] | ["Compensation","Nominating and Governance","Scientific","Scientific Committee"] | 2026 |
| Peter A. Demopulos, M.D. | Director | 72 | ["Practicing board-certified general and interventional cardiologist","Medical Director at Seattle Cardiology from 2005 to 2010","Clinical assistant professor of cardiology at the University of Washington School of Medicine since 1989","Fellow of the American College of Cardiology","Fellow of the Society for Cardiovascular Angiography and Interventions","Participant as an investigator in clinical trials evaluating interventional cardiology devices and drug therapies","Medical and scientific expertise","Experience as a clinical investigator","Experience with clinical development and trial design","Knowledge of Omeros and the industry"] | ["Scientific","Scientific Committee"] | 2026 |
| Rajiv Shah, M.D. | Director | 53 | ["significant experience in government","regulatory affairs","international development","strategic partnerships","medical background","scientific background"] | ["Audit","Compensation","Scientific","Scientific Committee"] | 2026 |
| Thomas F. Bumol, Ph.D. | Director; Chair | 72 | ["served as Executive Vice President of the Allen Institute for Immunology","35-year career at Eli Lilly and Company","senior vice president of biotechnology and immunology research","advanced over 100 molecules into clinical development","serves on the University of Michigan Technology Transfer National Advisory Board","advisor to Lilly Ventures","member of the Board of Directors of Tentarix Biotherapeutics LP","scientific advisor to a number of biotechnology and immunology companies","earned B.S. in microbiology from the University of Michigan","Ph.D. in microbiology-immunology from the University of Minnesota","postdoctoral studies in Molecular Immunology at Scripps Research"] | ["Scientific","AUDIT COMMITTEE","COMPENSATION COMMITTEE","NOMINATING AND GOVERNANCE COMMITTEE","Scientific Committee"] | 2026 |
| Thomas J. Cable | Director; Chair | 86 | ["Knowledge and experience in finance","Investment banking","Technology development and product commercialization","Knowledge of Omeros and its industry","Service as lead independent director","Chair of the compensation and nominating and governance committees"] | ["Audit","Compensation","Nominating and Governance","COMPENSATION COMMITTEE"] | 2026 |
